HD-OPM Archive
Topics › Cancer

Experimental pancreatic cancer drug nearly doubled overall survival, per CBS News

Louis Nervegna · Jun 01, 2026 · ♥ 6 reactions · 0 comments · original Facebook post
Cancer
AI summary & key facts

A shared CBS News item reporting that a new experimental drug nearly doubled survival in advanced pancreatic cancer. Little detail beyond the headline.

See this earlier post:
↪ Daraxonrasib raised 1-year survival from 18.7% to 53.3% in pancreatic cancer (NEJM)

#pancreaticcancerHD #daraxonrasibHD #cancerHD #rasHD #ascoHD #rasolute302HD

Research cited

A new, experimental medication nearly doubled overall survival rates for patients with advanced pancreatic cancer, according to the results of a study published Sunday. New drug nearly doubles survival rates in some pancreatic cancer patients, study says (CBS News)

← newer: Vitamin D analog paricalcitol raised tumour response from 9%older: Daraxonrasib raised 1-year survival from 18.7% to 53.3% in p →